Ether

Ether

SCHEMBL3761236

CCOCC.CO.FB(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL6535103 0.93 ALDH1A1 (0.37) ALDH1A1
Ether SCHEMBL40006 0.93
Ether SCHEMBL28855718 0.93 ALDH1A1 (0.37) ALDH1A1
Ether SCHEMBL9009598 0.93 ALDH1A1 (0.37) ALDH1A1
Ether SCHEMBL28468835 0.90 ALDH1A1 (0.45) ALDH1A1TSHR
Ether SCHEMBL23704984 0.89 ALDH1A1 (0.35) ALDH1A1
Ether SCHEMBL16446730 0.89 ALDH1A1 (0.35) ALDH1A1
Ether SCHEMBL2428958 0.86
Ether SCHEMBL10683113 0.86 ALDH1A1 (0.33) ALDH1A1
Ether SCHEMBL4526541 0.86 ALDH1A1 (0.33) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45128-E1 Cephalotaxane derivatives and their processes of preparation and purification IVAX International GmbH (CH) 2014-09-09 US disclosed
US-7842687-B2 Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration CHEMGENEX PHARMACEUTICALS, INC. (AU) 2010-11-30 US disclosed
US-7169774-B2 Cephalotaxane derivatives and their processes of preparation and purification STRAGEN PHARMA S.A. (CH) 2007-01-30 US disclosed
US-20060234999-A1 Cephalotaxane derivatives and their processes of preparation and purification TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2006-10-19 US disclosed
US-20050090484-A1 Cephalotaxane derivatives and their processes of preparation and purification IVAX International GmbH (CH) 2005-04-28 US disclosed
EP-1064285-B1 NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION STRAGEN PHARMA SA (CH) 2005-02-16 EP disclosed
US-6831180-B1 Substituted tertiary carboxylic oxacycloalkane acids, used to prepare anhydro-homo-harringtonic acids by semi-synthesis; hydroxyl function of a cephalotaxane is esterified with a 2-carboxyl-2-alkyl-1-oxacycloalkane claimed intermediate; (indexing from 7169774 added) STRAGEN PHARMA SA. (CH) 2004-12-14 US disclosed
US-6613900-B2 Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. ONCOPHARM CORPORATION 2003-09-02 US disclosed
US-20020045750-A1 Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. IVAX International GmbH (CH) 2002-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234999-A1 Cephalotaxane derivatives and their processes of preparation and purification UGT1A7, CYP8B1, UGT2B7 ALDH1A1 1136/4885TSHR 2148/4885
US-20020045750-A1 Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. AAAS, AARS1, AADAT ALDH1A1 804/4885TSHR 3354/4885
US-20050090484-A1 Cephalotaxane derivatives and their processes of preparation and purification UGT1A7, CYP8B1, UGT2B7 ALDH1A1 1136/4885TSHR 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.